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Introduction and Background

Results

Conclusion

Refractory asthma is an uncommon entity, manifesting in less
than five percent of asthmatics and characterized by high
medication requirements, persistent symptoms, frequent
exacerbations, and significant airflow obstruction despite
standard medical therapy.[1] Bronchoscopy may be an effective
tool for identifying refractory asthma phenotypes.[3] The
objective of this case series is to demonstrate the use of
bronchoscopy to personalize treatment among a population of
refractory asthmatics.

Prior to bronchoscopy, five patients required daily oral steroid
therapy with doses ranging from 5mg to 80mg and two patients
were receiving biologic therapies. Bronchoscopic evaluation
identified two patients with eosinophilic asthma, three patients
with a mixed phenotype of combined LPR and eosinophilic
asthma, and one patient with a mixed phenotype of SBI
(stenotrophomonas maltophilia) and eosinophilic asthma.
Eosinophilic asthma was determined by BAL eosinophils (range
1%-18%) despite oral prednisone therapy in five patients. Tissue
eosinophilia was confirmed in three patients (range 1-15 eos/hpf),
one of whom had no eosinophils by BAL.

As our comprehension of disease pathogenesis and the
treatment options at our disposal expand, the role for precision
medicine in asthma becomes increasingly evident. To date,
most phenotyping of asthma has been non-invasive and
includes spirometry, fractional exhaled nitric oxide (FENO),
and serum eosinophilia. Bronchoscopy can provide unique
information that can improve personalized care in patients
with refractory asthma.

Materials and Methods

Patient

This was a retrospective, observational chart review of patients
from a single outpatient pulmonary office. Patients who met
the American Thoracic Society guidelines for refractory asthma
and who underwent elective phenotyping bronchoscopy
between October 2017 and March 2019 were included in the
review. Diagnostic bronchoscopic evaluations were performed
following a framework laid out by Good et al, with a focus on
identifying laryngopharyngeal reflux (LPR), subacute bacterial
infection (SBI), and eosinophilia by endobronchial biopsy and
bronchoalveolar lavage (BAL).[3]
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The planned next step involves formal integration of
bronchoscopy into a clinical pathway for management of our
asthmatic patients, as detailed below.
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Following bronchoscopy, four patients were initiated on biologic
therapy (benralizumab, omalizumab), one patient was
transitioned from mepolizumab to benralizumab, three patients
underwent titration of GERD therapy along with dietary
modifications, and one patient received a course of antibiotics.
With these interventions all patients had significantly improved
asthma control and a reduction in exacerbations following
bronchoscopy guided therapy.

Focus Therapies/
Treat Alternate Diagnoses

References
1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS
guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-373.
2. Wenzel SE, Fahy JV, Irvin CG, Peters SP, Spector S, Szefler SJ. Proceedings of the ATS Workshop
on Refractory Asthma: current understanding, recommendations and unanswered questions. Am J
Respir Crit Care Med 2000;162:2341-2351.
3. Good, JT Jr, Kolakowski, CA, Groshong, SD, Murphy, JR, and Martin, RJ. Refractory asthma:
importance of bronchoscopy to identify phenotypes and direct therapy. Chest. 2012; 141: 599–606

